| Prev Close: | 1.33 |
|---|---|
| Open: | N/A |
| Bid: | 1.29 x 3300 |
| Ask: | 1.30 x 4700 |
| 1y Target Est: | 4.00 |
| Beta: | 1.17 |
| Next Earnings Date: | 29-Jul-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 1.02 - 3.94 |
| Volume: | 100,474 |
| Avg Vol (3m): | 999,480 |
| Market Cap: | 141.91M |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.57 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Cell Therapeutics announces new data demonstrating the safety and tolerability profile of Pacritinib in patients with myelofibrosisBriefing.com(Mon, Jun 17)
- CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with MyelofibrosisPR Newswire(Mon, Jun 17)
- New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab TreatmentPR Newswire(Mon, Jun 17)
- Cell Therapeutics to Join Russell 3000® and Russell Global IndexesPR Newswire(Mon, Jun 17)
- 5 Companies That Haven't Earned Their Keepat Motley Fool(Wed, Jun 12)
- CTI Announces Data Presentations at the 18th Congress of the European Hematology AssociationPR Newswire(Tue, Jun 11)
- 1 Biotech, 1 Tech Stock And 1 Apparel Store With Recent Intensive Insider Sellingat Seeking Alpha(Mon, Jun 10)
- Faruqi & Faruqi, LLP Launches An Investigation Against Cell Therapeutics, Inc. (CTIC) For Potential Breaches Of Fiduciary Duties By Its Board Of DirectorsBusiness Wire(Wed, Jun 5)
- CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast CancerPR Newswire(Sat, Jun 1)
- CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FiEDGAR Online(Fri, May 31)
- Cell Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PMat Seeking Alpha(Tue, May 21)
- German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)PR Newswire(Mon, May 20)
- Cell Therapeutics to Present at Upcoming Investor ConferencesPR Newswire(Wed, May 15)
- CELL THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 10)
- Cell Therapeutics Reports First Quarter 2013 Financial ResultsPR Newswire(Thu, May 2)
Press Releases
- CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with MyelofibrosisPR Newswire(Mon, Jun 17)
- New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab TreatmentPR Newswire(Mon, Jun 17)
- Cell Therapeutics to Join Russell 3000® and Russell Global IndexesPR Newswire(Mon, Jun 17)
Reports
- ValuEngine Industry Report for Medical-drugsValuEngine, Inc.(Jun 19)
- CELL THERAPEUTICS INC CDT-COM (CTIC) - REPORT FOR ACTIVE TRADERSPechala's Reports(Jun 17)
- Cell TherapeuticsS&P Capital IQ Quantitative Report(Jun 15)